A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma

Bendamustine has efficacy in multiple myeloma with a toxicity profile limited to myelosuppression. We hypothesized that adding bendamustine to autologous stem cell transplant conditioning in myeloma would enhance response without significant additional toxicity. We conducted a phase 1 trial adding e...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Mark, Tomer M., Reid, Whitney, Niesvizky, Ruben, Gergis, Usama, Pearse, Roger, Mayer, Sebastian, Greenberg, June, Coleman, Morton, Van Besien, Koen, Shore, Tsiporah
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3985064/
https://ncbi.nlm.nih.gov/pubmed/23454184
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2013.02.013
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires